Skip to main content
ACTRIS will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 to check if you are unsure if something is a scam or visit ScamShield (opens in new tab) for more information.

Advanced Cell Therapy and Research Institute, Singapore (ACTRIS)

Building Expertise in Cell Therapy: Insights from the CliniMACS Prodigy© Workshop

Topics

Workshop Highlights

29 April 2024

ACTRIS and Miltenyi Biotec held a hands-on workshop on GMP-compliant stem cell manufacturing. Participants gained practical skills in cell therapy production to drive innovation in targeted treatments.

Four-panel collage of people at ACTRIS lab: group photo, equipment demos, and a presentation with a projected slide.

Last week, our CliniMACS Prodigy© workshop brought together a diverse group of researchers, biotech manufacturing experts and graduate students specialising in cell therapy research, stem cell biology and GMP cell manufacturing for an insightful exchange.

Jointly organised with Miltenyi Biotec (opens in new tab), the workshop offered participants hands-on learning and a deep dive into the Adherent Cell Culture (ACC) process to learn how such systems enable the culture and expansion of stem cells in a GMP-compliant setting.

Likening the programming of manufacturing processes to the assembly of Lego blocks, Dr Kelly Wee, PhD and Dr Shu Cheng W., Technical and Application, Miltenyi Biotec, shed light on the benefits of consistent and scalable GMP-compliant manufacturing. It was an insightful afternoon where participants explored the system and customised sample modular applications.

Through these training initiatives, ACTRIS aims to equip the local cell therapy manufacturing workforce with the skills and knowledge required to effectively utilise new technologies, paving the way for greater innovation applications in targeted therapeutic interventions and improving patient outcomes. We hope to cultivate a community of knowledge experts in cell and gene therapy.

You may view our LinkedIn post here (opens in new tab).